Compare Illumina, Inc. (ILMN) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs IONQ Inc — how do they compare? Illumina, Inc. trades at $267.9 (market cap $39.95B), while IONQ Inc trades at $39.27 (market cap $15.98B). The key difference: Illumina, Inc. is far larger — about 2.5× IONQ Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and IONQ Inc for 33 Days on average.
| ILMN | IONQ | |
|---|---|---|
Market Cap | $39.95B | $15.98B |
Volume | 3,169,503 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $293.69 | $82.09 |
52-Week Low | $91.00 | $26.59 |
Typical Hold Time | 83 Days | 33 Days |
Enterprise Value | $41.31B | $13.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
IONQ trades at $39.19, down 5.2% in the last session, with a bearish technical outlook despite recent positive analyst coverage. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a net income margin of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss following two consecutive beats. The stock remains 50% below analyst consensus price target of $62.75, indicating substantial upside potential if execution improves.
IONQ presents a high-risk, high-reward opportunity with Wall Street divided (50% buy, 50% hold). The bullish case hinges on quantum computing leadership and partnerships with major cloud providers, while risks include persistent losses, cash burn, and execution challenges in a nascent market. Current valuation metrics (P/S: 54.74) reflect growth expectations rather than current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
